CLINICAL_TRIALS
trial_result
· 2025-08-08
Clinical Trial Update: Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer [Phase 3]
Summary
Phase 3 trial results evaluate adding darolutamide to androgen-deprivation therapy versus ADT alone in metastatic hormone-sensitive prostate cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2025-08-08